At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 6, 2026 at 08:00 ET
Acrivon Therapeutics acquired Aqilion AB's Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program for an undisclosed cash sum with no future milestone or royalty obligations. The acquisition establishes immunology and inflammation as a new strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first potential indication.
- Acquired ACR-525 (formerly AQ280), a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB
- Consideration was an undisclosed cash payment with no future milestone or royalty obligations
- Concurrently terminated all future royalty and milestone obligations on ACR-525 previously agreed between Aqilion and LEO Pharma
- Eosinophilic esophagitis (EoE) targeted as first potential indication using a formulation designed for difficulty swallowing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access